CN104622888B - The new application of garden burnet tannin and astragalus polyose - Google Patents
The new application of garden burnet tannin and astragalus polyose Download PDFInfo
- Publication number
- CN104622888B CN104622888B CN201410626070.8A CN201410626070A CN104622888B CN 104622888 B CN104622888 B CN 104622888B CN 201410626070 A CN201410626070 A CN 201410626070A CN 104622888 B CN104622888 B CN 104622888B
- Authority
- CN
- China
- Prior art keywords
- tannin
- garden burnet
- astragalus polyose
- bone marrow
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000173853 Sanguisorba officinalis Species 0.000 title claims abstract description 54
- 235000008291 Poterium sanguisorba Nutrition 0.000 title claims abstract description 53
- 235000008282 Sanguisorba officinalis Nutrition 0.000 title claims abstract description 53
- 235000006533 astragalus Nutrition 0.000 title claims abstract description 46
- 235000018553 tannin Nutrition 0.000 title claims abstract description 46
- 229920001864 tannin Polymers 0.000 title claims abstract description 46
- 239000001648 tannin Substances 0.000 title claims abstract description 46
- 241001061264 Astragalus Species 0.000 title claims abstract description 44
- 210000004233 talus Anatomy 0.000 title claims abstract description 44
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 24
- 230000001629 suppression Effects 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims description 22
- 210000000265 leukocyte Anatomy 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000890 drug combination Substances 0.000 abstract description 2
- 230000001976 improved effect Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 239000009636 Huang Qi Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000002798 bone marrow cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002607 hemopoietic effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 201000002364 leukopenia Diseases 0.000 description 3
- 231100001022 leukopenia Toxicity 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011122 softwood Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- 241000045403 Astragalus propinquus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides purposes of the garden burnet tannin in preparation and astragalus polyose drug combination are treated or/and prevent the medicine of bone marrow suppression.After garden burnet tannin and astragalus polyose are used in combination the present invention, synergistic function are played, its drug activity is significantly improved, new selection is provided for clinical application.
Description
Technical field
The invention provides garden burnet tannin and the new application of astragalus polyose.
Background technology
Bone marrow suppression is the most common and important complication of tumor chemoradiotherapy.Its peripheral white blood cells, it is hematoblastic substantially
Decline, lethal infection and bleeding can be triggered, process and the prognosis of oncotherapy is seriously limited.In worldwide and severe
The relevant treatment related mortality of bone marrow suppression is up to 4%~12%.Its reason overwhelming majority is that, because of serious bone marrow suppression, grain is thin
Various unmanageable infection caused by born of the same parents lack.In addition, stage of bone marrow heating, bleeding make patient to be in hospital the anti-sense of carry out system
Dye treatment, and hemostasis, blood transfusion etc., the medical expense of tumour patient is added indirectly, also deteriorates the quality of life of patient.Cause
This, bone marrow suppression is the dangerous obstacles for disturbing clinical tumor doctor to implement chemicotherapy therapeutic scheme, is also to hinder tumor patient health
Multiple lethal challenge.
At present, clinically to bone marrow suppression drug therapy and non-drug therapy can not all reach that the medication of clinician is needed
The need for summation is to patient's compliance.Either defeated component blood, or use Hemopoietic factor or peripheral stem cell transplantation, though
Right curative effect affirmative, but it is required for high cost.Simultaneously there is also the danger that infection is infected, the leucocyte being input into is in recipient's body
Occur that rejection is acted on, the time-to-live is shorter, and have the possibility for promoting cancerous swelling recurrence.And biological agent and chemicals all can only
For a certain class cytopenia, it is acted on, and single and side effect is big, it is impossible to plan as a whole marrow DNA and haemocyte rise.It is middle into
Medicine preparation works slow, it is impossible to meet after tumour patient chemicotherapy the need for the fast quick-recovery of constitution and secondary disease prevention.
Therefore, how to mitigate caused by radiotherapy and chemotherapy bone marrow suppression, promote hemopoietic function of bone marrow to recover, rise peripheral blood cells are
Ensure that chemicotherapy smoothly completes, improved the key issue of clinical tumor curative effect.Research and development material base is clear, the mechanism of action
Clearly, the little guarantor's marrow green blood natural drug of adverse reaction is extremely urgent.
Garden burnet is the rosaceous plant garden burnet Sanguisorba officinalis L. or garden burnet Sanguisorbad that comes into leaves
Officinalis L.var.longifolia (Bert.) Yuet Li dry root, first recorded in《Sheng Nong's herbal classic》, it is listed in
Middle product." its cold nature, bitter, acid, puckery, Return liver, large intestine channel ".With cooling blood and hemostasis, effect of removing toxic substances sore.Clinical data table
Bright, garden burnet raw medicinal herbs is notable to the therapeutic effect of tumor patient leukopenia caused by chemicotherapy, the small (5mg of dose
Work), Coming-of-Age Day takes maximum dose into only 60mg raw medicinal herbs, and modern study shows, the active material of garden burnet increasing leukocyte
Basis is saponin(e and tannin constituents.
The Radix Astragali is legume astragalus mongolicus Astragalus membranaceus (Fisch.)
Bge.var.mongholicus (Bge.) Hsiao or Astragalus membranacus Astragalus membranaceus (Fisch.) Bge.'s
Dry root, with multiple efficacies such as element culturing fixed folder, tonifying middle-Jiao and Qis.Modern study shows the Radix Astragali to leucocyte caused by a variety of causes
Disease is reduced, such as, due to tumor radiotherapy chemotherapy, by x-ray and the radiation of other radioactive substances, benzene poisoning, takes some antipyretic-antalgics
Medicine, leukopenia caused by the leukopenia caused by reason such as some infectious diseases and some unknown causes has
Good therapeutic action, its principle active component is astragalus polyose.
It there is no at present by the relevant report of the active component compatibility in the active component and the Radix Astragali in garden burnet.
The content of the invention
Modern study of the inventor based on garden burnet and Radix Astragali increasing leukocyte material base, it is theoretical and clinical in modern medicine
Under medication experience is instructed, based on clinical experience, using effect experiment as means, draft and being made up of garden burnet tannin and astragalus polyose
Pharmaceutical composition be the basic prescription of myelosuppresive therapy, then protect marrow according to astragalus polyose and garden burnet tannin and rise white clinical use
Amount is carried out etc. than baseline design as factor level, using quantity of leucocyte as MAIN OUTCOME MEASURES, observation different ratio dosage
Garden burnet tannin-influence of the astragalus polyose composition to endoxan inducing mouse bone marrow suppression, filters out optimal prescription and optimal
Proportion relation, the tcm componentses for research treatment bone marrow suppression lay the foundation.
It is an object of the invention to provide garden burnet tannin and the new application of astragalus polyose.Another object of the present invention is to carry
For a kind of pharmaceutical composition for treating or preventing bone marrow suppression.
Treated the invention provides garden burnet tannin in preparation and astragalus polyose drug combination or/and prevent the medicine of bone marrow suppression
Purposes in thing.
Further, garden burnet tannin and the weight of astragalus polyose ratio are 1~50：1~160.
Further, garden burnet tannin and the weight of astragalus polyose ratio are 25~30：55~60.
Preferably, garden burnet tannin and the weight of astragalus polyose ratio are 27：57.
Present invention also offers a kind of pharmaceutical composition treated or/and prevent bone marrow suppression, it is containing following weight
The preparation that the raw material of proportioning is prepared from：
Garden burnet tannin and the weight of astragalus polyose ratio are 1~50：1~160.
Further, garden burnet tannin and the weight of astragalus polyose ratio are 25~30：55~60.
Preferably, garden burnet tannin and the weight of astragalus polyose ratio are 27：57.
Wherein, content of tannin is 50~99% in the garden burnet tannin；Polyoses content is 50~99% in astragalus polyose.
Wherein, the preparation is oral formulations.
Present invention also offers purposes of the aforementioned pharmaceutical compositions in the medicine for treating or preventing bone marrow suppression is prepared.
Present invention also offers purposes of the aforementioned pharmaceutical compositions in the medicine with function of increasing leukocyte is prepared.
After garden burnet tannin and astragalus polyose are used in combination the present invention, synergistic function is played, its drug activity shows
Write and improve, new selection is provided for clinical application.
Brief description of the drawings
Each experimental mice peripheral white blood cell amounts of Fig. 1 (note：Compared with model group, * P<0.05, * * P<0.01；With ground
Elm tannin group group compares,△P<0.05,△△P<0.01；Compared with astragalus polyose group,▲P<0.05,▲▲P<0.01。)
Each experimental mice marrow DNA contents of Fig. 2(note：Compared with model group, * P<0.05, * * P<0.01；With
Garden burnet group compares,△P<0.05,△△P<0.01；Compared with Radix Astragali group,▲P<0.05,▲▲P<0.01。)
Each experimental mice candidate stem cell quantity of Fig. 3(note：Compared with model group, * P<0.05, * * P<
0.01；Compared with garden burnet group,△P<0.05,△△P<0.01；Compared with Radix Astragali group,▲P<0.05,▲▲P<0.01。)
Each experimental mice hematopoietic tissue capacity of Fig. 4(note：Compared with model group, * P<0.05, * * P<0.01；
Compared with garden burnet group,△P<0.05,△△P<0.01；Compared with Radix Astragali group,▲P<0.05,▲▲P<0.01。)
Embodiment
The tablet of embodiment 1
【Preparation method】Recipe quantity astragalus polyose and garden burnet tannin are taken, is added after auxiliary materials and mixing, 80 mesh sieves are crossed, then adds 95% second
Alcohol softwood, the granulation of 16 mesh nets；Whole grain after 60 DEG C of temperature are dried, then adds magnesium stearate 50g, mixes, and is pressed into 1000, bag
Clothing is produced.
The capsule of embodiment 2
【Preparation method】Recipe quantity astragalus polyose and garden burnet tannin are taken, is added after auxiliary materials and mixing, 80 mesh sieves are crossed, then adds 95% second
Alcohol softwood, the granulation of 16 mesh nets；Whole grain after 60 DEG C of temperature are dried, it is encapsulated, 1000 are made altogether.
The soft capsule of embodiment 3
【Preparation method】Recipe quantity astragalus polyose and garden burnet tannin are taken, 60 DEG C of dryings are ground into subdivision after being sufficiently mixed, add big
Soya-bean oil is mixed, and 1000 soft capsules are made.
The oral liquid of embodiment 4
【Preparation method】Recipe quantity astragalus polyose and garden burnet tannin are taken, adds the stirring of 1000ml pure water molten after being well mixed with auxiliary material
Solution, is mixed, and filtering is filling into 1000 bottles of oral liquids, sterilizing, thus obtaining the product.
The dripping pill of embodiment 5
【Preparation method】Take recipe quantity astragalus polyose and garden burnet tannin well mixed, add molten PEG-4000 and PEG-
6000, stir and evenly mix, instill dimethicone condensation shaping, 1000 balls are made in drop altogether.
The granule of embodiment 6
【Preparation method】Recipe quantity astragalus polyose and garden burnet tannin are taken, is added after auxiliary materials and mixing, 80 mesh sieves are crossed, then adds 95% second
Alcohol softwood, the granulation of 16 mesh nets；Whole grain after 60 DEG C of temperature are dried, packing dresses up 1000 bags altogether.
Beneficial effects of the present invention are illustrated below by way of test example.
The test of pesticide effectiveness of the drug therapy bone marrow suppression of the present invention of test example 1
1 experiment material
1.1 medicinal material
(1) garden burnet tannin (content is 50%~99%).
(2) astragalus polyose (content is 50%~99%).
1.2 positive drug：Recombinant humangranulocyte shoots down stimulating factor.
1.3 SPF grades of experimental animal KM mouse.
1.4 chemical reagent
(1) endoxan.(2) physiological saline.(3) absolute ethyl alcohol.(4) DMEM culture mediums.(5) hyclone.(6) it is dual anti-
(penicillin+streptomysin).
1.5 laboratory apparatus
(1) full-automatic blood cell analysis machine.(2) ultraviolet specrophotometer.(3) global function ELIASA.(4) constant-temperature table.(5)
Refiner.(6) refrigerated centrifuge.(7) flow cytometer.
2 experimental methods
2.1 medicine groups pair
Fully and effectively to carry out the screening of optimal drug compatibility and optimum dose proportion relation to primary election prescription, and as far as possible
Test number (TN) is reduced, this experiment use etc. carries out Formulation than base-line method.It is thin in vain with reference to garden burnet tannin and Effect of APS in Treating
Born of the same parents reduce the effective dose of disease for distribution rate baseline (garden burnet tannin:5~50mg, 40~160mg of astragalus polyose), the Radix Astragali is more therebetween
Sugared agent amount is successively decreased with 10~30%, and garden burnet tannin dosage is incremented by with 10~30%, or garden burnet tannin dosage is passed with 10~40%
Subtract, astragalus polyose dosage is incremented by with 10~40% to be extended to both sides, is finally expanded to limit, both sides limit is respectively the simple Radix Astragali
Polysaccharide and simple garden burnet tannin.With astragalus polyose and two kinds of medicines of garden burnet tannin it is several proportioning packet, according to research purpose with
Two medicine main effects and secondary efficacy are evaluation index, are analyzed by integrated information, carry out the optimal screening of each proportioning.Two medicines are matched somebody with somebody
1 is shown in Table than ratio.
The ratio baseline proportion design table such as the astragalus polyose of table 1 and garden burnet tannin
The pharmacological evaluation screening of 2.2 optimal doses
2.2.1 the preparation of test medicine
Weigh the astragalus polyose and garden burnet tannin of 1~9 dosage group respectively by composition consumption in table 1, be separately added into certain
The dissolved in purified water of volume is mixed, and obtains 1~9 group of medicinal composition solution.
2.2.2 experiment packet and administration
All Animal adaptabilities are randomly divided into after feeding 1 week by body weight：Normal group, model group, positive group (granular leukocyte colony
Stimulating factor group)；1~9 group of extract, every group 12.Each experimental group is given by 0.2ml/kg dosage gavages since the experimental day
Give relative medicine, normal group and the isometric pure water of model group mouse stomach, continuous 10 days.
2.2.3 animal model is prepared and collection of specimens
Test the 4th day, in addition to blank group, remaining each group mouse presses 100mgkg-1Dosage intraperitoneal injection of cyclophosphamide physiology
Saline solution, continuous 4 days, isometric physiological saline was injected intraperitoneally in naive mice.Test the 10th day, each experimental mice eye socket
Blood is taken, collects to be measured with the 0.5mlEP pipes equipped with EDTA anti-coagulants；Disconnected neck puts to death mouse, takes left and right sides femur in ultra-clean work
Make on platform, cleared muscle and connective tissue.
2.2.4 Testing index and method
1. peripheral hemogram is detected：Each experimental mice peripheral white blood cells (WBC) are entered using full-automatic blood counting instrument
Row is counted.
2. marrow DNA content is determined：Mouse left rear limb femur is peeled off, is cut with ophthalmologic operation and cuts femur two ends, is revealed
Go out ossis.With 10ml0.005mol/L CaCl2Marrow is rinsed into centrifuge tube, 4 DEG C of refrigerators place 30min, 2500r/min
Centrifuge 15min.Supernatant is abandoned, 0.2mo1/L HClO are added4Solution 5ml, after vibration is mixed, 90 DEG C of heating 15min.It is cold with flowing water
But to room temperature cooled and filtered, filtrate determines 268nm absorbance A value through ultraviolet specrophotometer.
3. Bone Marrow Hematopoietic Stem counts (HSPC, using candidate stem cell phenotype molecule CD34 as label) with containing bovine serum albumin
White concentration goes out right side of mice femur bone marrow cell for 0.2% PBS, takes out 106Individual cell centrifugation, abandons supernatant, plus
Enter 30 μ L Normal Mouse Serums to close unspecific binding sites, the rat anti-mouse CD34 for adding 10 μ L FITC marks resists
Body, control tube adds the corresponding control antibodies of 10 μ L, and 4 DEG C of lucifuges react 30min.2mL erythrocyte cracked liquids are added, 5min is acted on,
Wash cell 2 times, final concentration of 3 μ g/mL PI dye liquors are added, using flow cytomery bone marrow cell CD34+Antigen presentation.
4. marrow protection Morphology observation：Part marrow is taken, 10% neutral formalin is fixed, plastic embedding, femur stage casing
Marrow hematopoietic capacity percentage change is observed under slices across, Giemsa dyeing, high power light microscopic.
2.3 statistical method
Statistical analysis is carried out using SPSS17.0 softwares, data are with mean ± standard deviationRepresent, using single between group
LSD inspections are carried out between analysis of variance, the neat person's group of variance, heterogeneity of variance person carries out Tamhane ' sT2 and examined.
2.4 experimental result
2.4.1 the influence result to bone marrow suppression mouse peripheral blood cell quantity is shown in Fig. 1.
As shown in Figure 1, compared with normal group, model group mouse peripheral blood WBC has pole to significantly reduce (P<0.01)；With model
Group compares, and 1~9 group of mouse peripheral blood WBC of composition has significantly rise (P<0.05), wherein, 6 groups of composition has extremely notable liter
Height (P<0.01)；Compared with garden burnet tannin, astragalus polyose group, 1~9 group of mouse peripheral blood WBC of composition has rise trend, group
6 groups of mouse peripheral blood WBC of compound have significantly rise (P<0.05).
2.5.2 the influence result to bone marrow suppression mouse DNA content is shown in Fig. 2.
As shown in Figure 2, compared with normal group, model group mouse bone marrow cells DNA content has pole to significantly reduce (P<0.01)；With mould
Type group compares, and 1~9 group of mouse bone marrow cells DNA content of composition has significantly rise (P<0.05), wherein, 6 groups of composition have extremely show
Write rise (P<0.01)；Compared with garden burnet tannin, astragalus polyose group, 1~9 group of marrow DNA content of composition has rise trend,
6 groups of mouse bone marrow cells DNA contents of composition have significantly rise (P<0.05).
2.5.3 the influence result to bone marrow suppression mouse hematopoietic stem cell quantity is shown in Fig. 3.
From the figure 3, it may be seen that being compared with normal group, model group mouse hematopoietic stem cell quantity has pole to significantly reduce (P<0.01)；
Compared with model group, 1~9 group of mouse hematopoietic stem cell quantity of composition has significantly rise (P<0.05), wherein, composition 6
Group has extremely notable rise (P<0.01)；Compared with garden burnet tannin, astragalus polyose group, 1~9 group of candidate stem cell quantity of composition is equal
There is rise trend, 6 groups of mouse hematopoietic stem cell quantity of composition have significantly rise (P<0.05).
2.5.4 the influence result to bone marrow suppression mouse hemopoietic volume of tissue is shown in Fig. 4.
As shown in Figure 4, compared with normal group, model group mouse hemopoietic volume of tissue has pole to significantly reduce (P<0.01)；With
Model group compares, and 1~9 group of mouse hemopoietic volume of tissue of composition has significantly rise (P<0.05), wherein, 6 groups of composition has
Extremely significantly rise (P<0.01)；Compared with garden burnet tannin, astragalus polyose group, 1~9 group of composition, which makes hematopoietic tissue capacity, liter
High trend, 6 groups of mouse hemopoietic volume of tissue of composition have significantly rise (P<0.05).
3 experiment conclusions
(1) 9 kinds of ratio compatibilities of astragalus polyose and garden burnet tannin suppress to be respectively provided with well to caused by cyclophosphamide mouse bone marrow cells
Therapeutic action, and the therapeutic effect of various ratio compatibilities is superior to astragalus polyose and garden burnet tannin is alone.
(2) optimal proportion of Radix Astragali compatibility garden burnet treatment bone marrow suppression is 52mg:27mg.
Claims (6)
1. purposes of the garden burnet tannin with astragalus polyose in the combination medicine for preparing treatment or/and prevention bone marrow suppression；Garden burnet
Tannin and the weight of astragalus polyose ratio are 27：52.
2. a kind of pharmaceutical composition treated or/and prevent bone marrow suppression, it is characterised in that：It contains following weight proportion
The preparation that bulk drug is prepared from：Garden burnet tannin and the weight of astragalus polyose compare 27：52.
3. pharmaceutical composition according to claim 2, it is characterised in that：In the garden burnet tannin content of tannin be 50~
99%；Polyoses content is 50~99% in astragalus polyose.
4. the pharmaceutical composition according to Claims 2 or 3, it is characterised in that：The preparation is oral formulations.
5. Claims 2 or 3 described pharmaceutical composition is in the medicine for treating or preventing bone marrow suppression or increasing leukocyte is prepared
Purposes.
6. use of claim 4 described pharmaceutical composition in the medicine for treating or preventing bone marrow suppression or increasing leukocyte is prepared
On the way.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626070.8A CN104622888B (en) | 2013-11-08 | 2014-11-07 | The new application of garden burnet tannin and astragalus polyose |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013105542098 | 2013-11-08 | ||
| CN201310554209 | 2013-11-08 | ||
| CN201410626070.8A CN104622888B (en) | 2013-11-08 | 2014-11-07 | The new application of garden burnet tannin and astragalus polyose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104622888A CN104622888A (en) | 2015-05-20 |
| CN104622888B true CN104622888B (en) | 2017-09-15 |
Family
ID=53202451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410626070.8A Active CN104622888B (en) | 2013-11-08 | 2014-11-07 | The new application of garden burnet tannin and astragalus polyose |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104622888B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102406731B (en) * | 2010-12-01 | 2013-12-11 | 成都科尔医药技术有限公司 | Combination medicament for preventing or/and treating bone marrow suppression |
| CN102895515B (en) * | 2011-06-29 | 2015-07-15 | 上海中医药大学附属龙华医院 | Chinese medicinal composition for raising leucocytes and preparation method and application thereof |
-
2014
- 2014-11-07 CN CN201410626070.8A patent/CN104622888B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104622888A (en) | 2015-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2428974A (en) | Botanical drug or dietary supplement | |
| CN101396466A (en) | Cold medicine tea composition as medicine and food, preparation method and use thereof | |
| CN109999099A (en) | A kind of Chinese medicine composition and its preparation method and application for the deficiency of blood | |
| CN104127808B (en) | Treat Chinese medicine preparation of malignant tumour and preparation method thereof | |
| CN102793715A (en) | Sargassum polysaccharide and application of Sargassum polysaccharide in medicine preparation used for treating kidney injury | |
| CN100361681C (en) | Medicine for treating thrombocytopenia and anemia and its prepn process and quality control method | |
| CN102389559B (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| CN104622888B (en) | The new application of garden burnet tannin and astragalus polyose | |
| CN101181285A (en) | Application of astragaloside IV in the preparation of medicament for curing nervus retrogression disease | |
| CN106389764B (en) | A kind of Chinese materia medica preparation and its preparation and application | |
| CN102652774A (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| CN103027906A (en) | Application of arctigenin in treating anemia | |
| CN102861192B (en) | Medicine composition for chronic renal failure and peritoneal fibrosis | |
| CN102716260B (en) | Medicine for fast improving sperm quality and sexual function | |
| CN104623015A (en) | New application of garden burnet root and India madder root composition | |
| CN101721612B (en) | Chinese medicinal composition for raising leucocytes and preparation method and application thereof | |
| CN101181440B (en) | Chinese medicine composition for curing hemopathy as well as preparation method and usage thereof | |
| CN104887766A (en) | Traditional Chinese medicine compound capsules for treating atherosclerosis and preparation method thereof | |
| CN104547105A (en) | Agent for reducing blood glucose | |
| CN104435220B (en) | Treat the combination medicine of bone marrow suppression | |
| CN104688723A (en) | Application of anhydroicaritin in preparation of medicine for treating anaemia | |
| CN102872374B (en) | Chinese medicinal composition for assisting tumor radiotherapy | |
| CN1233416C (en) | Compound pepsin powder for treating child dyspepsia and its preparation method | |
| CN1100550C (en) | Chinese medicine composition for curing various cancers | |
| CN102406869B (en) | Intestine-protecting and detoxifying micro pellets and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200330 Address after: 530000 changshuiling Industrial Park, Maling Town, Lipu County, Guilin City, Guangxi Zhuang Autonomous Region Patentee after: Guangxi Yingluweite Pharmaceutical Co.,Ltd. Address before: High tech Zone Gaopeng road in Chengdu city of Sichuan province 610000 5 Building No. 1 room 206 Patentee before: CHENGDU BAICAO HEJI TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: New Applications of Tannins from Ulmus officinalis and Polysaccharides from Astragalus membranaceus Granted publication date: 20170915 Pledgee: Financing Company limited by guarantee of small and micro enterprises in Guilin Pledgor: Guangxi Yingluweite Pharmaceutical Co.,Ltd. Registration number: Y2024980013432 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |